

## Introduction

BioCAID has developed a Deep Learning AI technology positioned as a horizontal platform with visual navigation applications across broad segments of the Healthcare IT marketplace. Here are some key take-aways from our business plan and proforma:

- ✓ Our first product is a “Freemium” advertising model application launched 6 months after seed funding and release of the IMDI (Intelligent Medline Discovery Integration) SaaS beta. IMDI and Freemium are foundational to our business plan with intuitive features that address known user needs and targeted markets.
- ✓ We have validated a method to identify an untapped Freemium marketplace of 6,000,000 plus monthly Internet Home Health Search (HHS) users specifically seeking scientific journals and publications in the biomedical, life sciences and healthcare industries. Validation is directly based on data and projections from Google and our method.
- ✓ The Freemium offering on the IMDI SaaS platform will scale into Professional and Enterprise site-license versions with advanced open and closed literature discovery and decision support AI driving high value research and innovation ROI.
- ✓ A quick review of the [www.biocaid.com](http://www.biocaid.com) website “How it works” short video shows how BioCAID visual representation and navigation of known and hidden relationships presents users with an interactive knowledge-based comprehension improvement over Internet Search that supports open and closed literature discovery. Brief PDF pages under the “Info” menu describe the algorithms.
- ✓ There is a sophisticated IP value chaining model that presents significant opportunity to leverage BioCAID marketing and establishes a strong barrier to entry for new competitors and obstacle for current competitors to respond in kind.
- ✓ BioCAID has released a PPM with a Convertible Note offering overlapping a Series A Preferred for \$3.6 million funding. The business plan describes an investment opportunity in an AI software startup Go To Marketing company leveraging the IP portfolio and technologies incorporating years of prior peer-reviewed research and prototype development investments. Use of fund builds the IMDI commercial scalable secure SaaS platform and Freemium application launch to profit-based operations, making BioCAID very efficient in our financing requirements.

If the BioCAID opportunity fits your investment, we should proceed with further thoughtful discussion. We have prepared a Due Diligence Investor Portal within [www.biocaid.com](http://www.biocaid.com). To receive login credentials, send an email to Karen Rands, Business Development and Investor Relations at [krands@biocaid.com](mailto:krands@biocaid.com) or email me at [tpresti@biocaid.com](mailto:tpresti@biocaid.com) with that specific request and I'll arrange it with Karen on your behalf. Thank you for your review and consideration of this opportunity and I look forward to our next conversation.

Regards,



Anthony Prestigiacomo, CEO  
BioCAID, Inc.